This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Jun 2014

Promega Introduces New Mass Spec Reagents, IdeS Protease and Human and Yeast Protein Extracts

Promega Corporation announces the launch of new products for scientists working with mass spectrometry. The IdeS Protease enables fast, easy, high performance digestion of immunoglobulin, while the Human and Yeast Protein Extracts provide a test material for optimizing mass spec sample preparation. The new products add to the company’s existing range of proteases and services to improve mass spec sample prep workflows.


IdeS Protease is a recombinant, engineered version of the immunoglobulin-degrading enzyme from Streptococcus pyogenes. It is a highly specific protease that slices Immunoglobulin G (IgG) at a single, targeted site, offering 100% digestion in 30 minutes with no optimization. IdeS can be used to characterize therapeutic antibody candidates using LC/MS, and contains a histidine tag for easy removal. The versatile Promega IdeS enzyme cuts IgGs from a range of species, as well as Fc-fusion proteins.


The new yeast and human protein extracts are designed specifically for mass spectrometry applications. Available in either predigested, cleaned form for immediate use in LC/MS analysis or intact, undigested form to provide a test material for optimizing mass spec protein sample preparation, the extracts provide clean, consistent, quantified, model system samples for LC/MS method development and instrument monitoring. The yeast extracts are beneficial for users who prefer working with a relatively compact and well-studied proteome, whereas the human extract, with large dynamic range, provides the opportunity to work with complex proteomes. The new products are: MS Compatible Yeast Protein Extract, Digest; MS Compatible Human Protein Extract, Digest; MS Compatible Yeast Protein Extract, Intact; and MS Compatible Human Protein Extract, Intact.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.